[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100480450":3},{"organization":4,"armGroups":7,"interventions":64,"overallOfficials":84,"centralContacts":89,"locations":94,"responsibleParty":303,"collaborators":75,"id":305,"slug":306,"hasResults":307,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":307,"sex":313,"minAge":314,"maxAge":75,"enrollmentInfo":315,"targetDuration":75,"studyType":318,"phases":319,"briefSummary":321,"conditions":322,"keywords":325,"overallStatus":97,"whyStopped":75,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},{"fullName":5,"class":6},"Arcus Biosciences, Inc.","INDUSTRY",[8,14,17,21,24,27,31,34,37,42,45,48,53,56,61],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Cohort 1","EXPERIMENTAL","Participants will receive casdatifan orally once daily",[13],"Drug: casdatifan",{"label":15,"type":10,"description":11,"interventionNames":16},"Dose Escalation Cohort 2",[13],{"label":18,"type":10,"description":19,"interventionNames":20},"Dose Escalation Cohort 3","Participants will receive casdatifan orally twice daily",[13],{"label":22,"type":10,"description":11,"interventionNames":23},"Dose Escalation Cohort 4",[13],{"label":25,"type":10,"description":11,"interventionNames":26},"Dose Escalation Cohort 5",[13],{"label":28,"type":10,"description":29,"interventionNames":30},"Dose Expansion Cohort 1","Participants will receive casdatifan orally",[13],{"label":32,"type":10,"description":29,"interventionNames":33},"Dose Expansion Cohort 2",[13],{"label":35,"type":10,"description":29,"interventionNames":36},"Dose Expansion Cohort 3",[13],{"label":38,"type":10,"description":39,"interventionNames":40},"Dose Expansion Cohort 4","Participants will receive casdatifan orally with with cabozantinib orally",[13,41],"Drug: Cabozantinib",{"label":43,"type":10,"description":29,"interventionNames":44},"Dose Expansion Cohort 5",[13],{"label":46,"type":10,"description":29,"interventionNames":47},"Dose Expansion Cohort 6",[13],{"label":49,"type":10,"description":50,"interventionNames":51},"Dose Expansion Cohort 7","Participants will receive casdatifan orally with zimberelimab infusion",[13,52],"Drug: Zimberelimab",{"label":54,"type":10,"description":29,"interventionNames":55},"Dose Expansion Cohort 8",[13],{"label":57,"type":10,"description":58,"interventionNames":59},"Dose Expansion Cohort 9","Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion",[13,52,60],"Drug: Ipilimumab",{"label":62,"type":10,"description":58,"interventionNames":63},"Dose Expansion Cohort 10",[13,52,60],[65,72,76,81],{"type":66,"name":67,"description":68,"armGroupLabels":69,"otherNames":70},"DRUG","casdatifan","Administered as specified in the treatment arm",[9,15,18,22,25,28,62,32,35,38,43,46,49,54,57],[71],"AB521",{"type":66,"name":73,"description":68,"armGroupLabels":74,"otherNames":75},"Cabozantinib",[38],null,{"type":66,"name":77,"description":68,"armGroupLabels":78,"otherNames":79},"Zimberelimab",[62,49,57],[80],"AB122",{"type":66,"name":82,"description":68,"armGroupLabels":83,"otherNames":75},"Ipilimumab",[62,57],[85],{"name":86,"affiliation":87,"role":88},"Medical Director","Arcus Biosciences","STUDY_DIRECTOR",[90],{"name":86,"role":91,"phone":92,"phoneExt":75,"email":93},"CONTACT","+1-510-462-3330","ClinicalTrialInquiry@arcusbio.com",[95,109,118,126,135,144,153,162,171,180,189,194,203,211,216,225,230,239,248,253,262,272,279,286,294],{"facility":96,"status":97,"city":98,"state":99,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":108,"contacts":75},"Research Site","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":104,"coordinates":105},"Point",[106,107],-86.80249,33.52066,{"lat":107,"lon":106},{"facility":96,"status":97,"city":110,"state":111,"zip":112,"country":101,"countryCode":102,"cosmosGeoPoint":113,"geoPoint":117,"contacts":75},"San Diego","California","92093",{"type":104,"coordinates":114},[115,116],-117.16472,32.71571,{"lat":116,"lon":115},{"facility":96,"status":97,"city":119,"state":111,"zip":120,"country":101,"countryCode":102,"cosmosGeoPoint":121,"geoPoint":125,"contacts":75},"Santa Monica","90404",{"type":104,"coordinates":122},[123,124],-118.49138,34.01949,{"lat":124,"lon":123},{"facility":96,"status":97,"city":127,"state":128,"zip":129,"country":101,"countryCode":102,"cosmosGeoPoint":130,"geoPoint":134,"contacts":75},"Miami","Florida","33136",{"type":104,"coordinates":131},[132,133],-80.19366,25.77427,{"lat":133,"lon":132},{"facility":96,"status":97,"city":136,"state":137,"zip":138,"country":101,"countryCode":102,"cosmosGeoPoint":139,"geoPoint":143,"contacts":75},"Atlanta","Georgia","30322-1013",{"type":104,"coordinates":140},[141,142],-84.38798,33.749,{"lat":142,"lon":141},{"facility":96,"status":97,"city":145,"state":146,"zip":147,"country":101,"countryCode":102,"cosmosGeoPoint":148,"geoPoint":152,"contacts":75},"Louisville","Kentucky","40202",{"type":104,"coordinates":149},[150,151],-85.75941,38.25424,{"lat":151,"lon":150},{"facility":96,"status":97,"city":154,"state":155,"zip":156,"country":101,"countryCode":102,"cosmosGeoPoint":157,"geoPoint":161,"contacts":75},"New Orleans","Louisiana","70121",{"type":104,"coordinates":158},[159,160],-90.07507,29.95465,{"lat":160,"lon":159},{"facility":96,"status":97,"city":163,"state":164,"zip":165,"country":101,"countryCode":102,"cosmosGeoPoint":166,"geoPoint":170,"contacts":75},"Baltimore","Maryland","21287",{"type":104,"coordinates":167},[168,169],-76.61219,39.29038,{"lat":169,"lon":168},{"facility":96,"status":97,"city":172,"state":173,"zip":174,"country":101,"countryCode":102,"cosmosGeoPoint":175,"geoPoint":179,"contacts":75},"Boston","Massachusetts","02215",{"type":104,"coordinates":176},[177,178],-71.05977,42.35843,{"lat":178,"lon":177},{"facility":96,"status":97,"city":181,"state":182,"zip":183,"country":101,"countryCode":102,"cosmosGeoPoint":184,"geoPoint":188,"contacts":75},"Detroit","Michigan","48201",{"type":104,"coordinates":185},[186,187],-83.04575,42.33143,{"lat":187,"lon":186},{"facility":96,"status":97,"city":181,"state":182,"zip":190,"country":101,"countryCode":102,"cosmosGeoPoint":191,"geoPoint":193,"contacts":75},"48202",{"type":104,"coordinates":192},[186,187],{"lat":187,"lon":186},{"facility":96,"status":97,"city":195,"state":196,"zip":197,"country":101,"countryCode":102,"cosmosGeoPoint":198,"geoPoint":202,"contacts":75},"Omaha","Nebraska","68124",{"type":104,"coordinates":199},[200,201],-95.94043,41.25626,{"lat":201,"lon":200},{"facility":96,"status":97,"city":204,"state":204,"zip":205,"country":101,"countryCode":102,"cosmosGeoPoint":206,"geoPoint":210,"contacts":75},"New York","10029",{"type":104,"coordinates":207},[208,209],-74.00597,40.71427,{"lat":209,"lon":208},{"facility":96,"status":97,"city":204,"state":204,"zip":212,"country":101,"countryCode":102,"cosmosGeoPoint":213,"geoPoint":215,"contacts":75},"10065",{"type":104,"coordinates":214},[208,209],{"lat":209,"lon":208},{"facility":96,"status":97,"city":217,"state":218,"zip":219,"country":101,"countryCode":102,"cosmosGeoPoint":220,"geoPoint":224,"contacts":75},"Cleveland","Ohio","44106",{"type":104,"coordinates":221},[222,223],-81.69541,41.4995,{"lat":223,"lon":222},{"facility":96,"status":97,"city":217,"state":218,"zip":226,"country":101,"countryCode":102,"cosmosGeoPoint":227,"geoPoint":229,"contacts":75},"44195",{"type":104,"coordinates":228},[222,223],{"lat":223,"lon":222},{"facility":96,"status":97,"city":231,"state":232,"zip":233,"country":101,"countryCode":102,"cosmosGeoPoint":234,"geoPoint":238,"contacts":75},"Pittsburgh","Pennsylvania","15232",{"type":104,"coordinates":235},[236,237],-79.99589,40.44062,{"lat":237,"lon":236},{"facility":96,"status":97,"city":240,"state":241,"zip":242,"country":101,"countryCode":102,"cosmosGeoPoint":243,"geoPoint":247,"contacts":75},"Nashville","Tennessee","37203",{"type":104,"coordinates":244},[245,246],-86.78444,36.16589,{"lat":246,"lon":245},{"facility":96,"status":97,"city":240,"state":241,"zip":249,"country":101,"countryCode":102,"cosmosGeoPoint":250,"geoPoint":252,"contacts":75},"37240",{"type":104,"coordinates":251},[245,246],{"lat":246,"lon":245},{"facility":96,"status":97,"city":254,"state":255,"zip":256,"country":101,"countryCode":102,"cosmosGeoPoint":257,"geoPoint":261,"contacts":75},"San Antonio","Texas","78229",{"type":104,"coordinates":258},[259,260],-98.49363,29.42412,{"lat":260,"lon":259},{"facility":96,"status":263,"city":264,"state":75,"zip":75,"country":265,"countryCode":266,"cosmosGeoPoint":267,"geoPoint":271,"contacts":75},"NOT_YET_RECRUITING","Camperdown","Australia","AU",{"type":104,"coordinates":268},[269,270],151.17642,-33.88965,{"lat":270,"lon":269},{"facility":96,"status":97,"city":273,"state":75,"zip":75,"country":265,"countryCode":266,"cosmosGeoPoint":274,"geoPoint":278,"contacts":75},"Melbourne",{"type":104,"coordinates":275},[276,277],144.96332,-37.814,{"lat":277,"lon":276},{"facility":96,"status":97,"city":280,"state":75,"zip":75,"country":265,"countryCode":266,"cosmosGeoPoint":281,"geoPoint":285,"contacts":75},"Sydney",{"type":104,"coordinates":282},[283,284],151.20732,-33.86785,{"lat":284,"lon":283},{"facility":96,"status":97,"city":287,"state":75,"zip":75,"country":288,"countryCode":75,"cosmosGeoPoint":289,"geoPoint":293,"contacts":75},"Seoul","South Korea",{"type":104,"coordinates":290},[291,292],126.9784,37.566,{"lat":292,"lon":291},{"facility":96,"status":97,"city":295,"state":75,"zip":75,"country":296,"countryCode":297,"cosmosGeoPoint":298,"geoPoint":302,"contacts":75},"Barcelona","Spain","ES",{"type":104,"coordinates":299},[300,301],2.15899,41.38879,{"lat":301,"lon":300},{"type":304,"investigatorFullName":75,"investigatorTitle":75,"investigatorAffiliation":75,"oldNameTitle":75,"oldOrganization":75},"SPONSOR","100480450","phase-1-a-phase-1-study-of-ab521-monotherapy-and-combination-therapies-in-renal-cell-carcinoma-and-other-solid-tumors-100480450",false,"NCT05536141","A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors","ARC-20","Key Inclusion Criteria:\n\n* Must have at least one measurable lesion per RECIST guidance\n* Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1\n* Disease-specific criteria for dose escalation:\n\n  * Participants may have any pathologically confirmed solid tumor type where no other treatment options are available\n  * Creatinine clearance ≥ 40 mL\u002Fmin\n\nDisease-specific criteria for dose-expansion:\n\n* Histologically confirmed ccRCC\n* Creatinine clearance ≥ 40 mL\u002Fmin\n\nKey Exclusion Criteria:\n\n* Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product\n* Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous\n* History of trauma or major surgery within 28 days prior to the first dose of investigational product\n* For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor. For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":316,"type":317},362,"ESTIMATED","INTERVENTIONAL",[320],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of:\n\n* casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and\n* casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.",[323,324],"Clear Cell Renal Cell Carcinoma","Solid Tumors",[323,71,326,327,77,80,328],"Casdatifan","Kidney Cancer","Hif2a","2026-07-01",{"date":331,"type":332},"2026-07-02","ACTUAL",{"date":334,"type":332},"2022-10-26",{"date":336,"type":317},"2029-03",{"name":5,"class":6},25]